<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727034</url>
  </required_header>
  <id_info>
    <org_study_id>sudiansan1215</org_study_id>
    <nct_id>NCT04727034</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy</brief_title>
  <official_title>A Multicenter, Randomized, Single-blind, Parallel Controlled Clinical Study on the Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial People's Hopital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Jiaxing University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but&#xD;
      propofol significantly inhibits the respiratory and circulatory systems. Therefore, the&#xD;
      incidence of intraoperative hypoxemia and hypotension is high. Remazolam tosylate is an&#xD;
      ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory&#xD;
      and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate&#xD;
      very likely to replace propofol in painless gastroscopic anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate of remazolam tosylate for sedation in gastroscopy diagnosis and treatment</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>1) Complete the entire process of gastroscopy; 2) No sedative remedy is given; 3) After the initial dose of the test drug is administered, additional administration ≤ 2 times within any 5-minute period; 4) The initial dose of propofol After the end, within any 5-minute period of additional administration ≤ 2 times, it is recorded as propofol (control group) successfully sedated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation induction time</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>induction time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation recovery time</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>recovery time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug injection pain</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>drug injection pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doctor satisfaction and patient satisfaction</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>There is a scale from 1 to 10. Endoscopists and patients will score their satisfaction with the scale ,with 1-3 (dissatisfied),4-6 (satisfied) and 7-10 (very satisfied) after gastroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time it takes for the patient to wake up and leave the hospital if the Sedation/Anaesthesia Discharge Rating Scale score exceeds 9 points;</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>Sedation/Anaesthesia Discharge Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hypoxia during sedation</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>(75% ≤ SpO2 &lt; 90% for &lt;60 s)；(SpO2 &lt; 75% for any duration or 75% &lt; SpO2 &lt; 90% for &gt;/=60 s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other adverse events assessed by the World SIVA adverse sedation event reporting tool</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Hypoxia</condition>
  <condition>Gastric Cancer</condition>
  <condition>Sedation Complication</condition>
  <condition>Propofol Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol（1.5mg/kg）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group 1（Remimazolam tosylate 0.15mg/kg）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam tosylate 0.15mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group 2（Remimazolam tosylate 0.2mg/kg）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam tosylate 0.2mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam tosylate</intervention_name>
    <description>Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.</description>
    <arm_group_label>Test group 1（Remimazolam tosylate 0.15mg/kg）</arm_group_label>
    <arm_group_label>Test group 2（Remimazolam tosylate 0.2mg/kg）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 1)18≤age≤60 years old, no gender limit; 2) Patients receiving routine gastroscopy&#xD;
        diagnosis and treatment; 3) ASA score is I or II; 4) 18 kg/m2&lt;BMI&lt;28kg/m2； 5) It is&#xD;
        estimated that the operation time of gastroscope will not exceed 30 minutes; 6) Clearly&#xD;
        understand, voluntarily participate in the research, and be signed and informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Need to perform complicated endoscopic diagnosis and treatment techniques (such as&#xD;
             cholangiopancreatography Surgery, endoscopic ultrasonography, endoscopic mucosal&#xD;
             resection, endoscopic submucosa Stripping, oral endoscopic muscle dissection, etc.);&#xD;
&#xD;
          2. Patients who intend to undergo tracheal intubation;&#xD;
&#xD;
          3. It is judged to be difficult to manage the respiratory tract (modified Mallampati&#xD;
             score is IV)patient;&#xD;
&#xD;
          4. Anemia or thrombocytopenia,( Hb&lt;90g/L, PLT&lt;80×109/L);&#xD;
&#xD;
          5. Diagnosed lung diseases (asthma, bronchitis, COPD, Pulmonary bullae,pulmonary&#xD;
             embolism, pulmonary edema, lung cancer);&#xD;
&#xD;
          6. Liver and kidney disease;( AST and/or ALT≥2.5×ULN,TBIL≥1.5×ULN, blood creatinine is&#xD;
             greater than the upper limit of normal);&#xD;
&#xD;
          7. There is a history of drug and/or alcohol abuse within 2 years before the beginning of&#xD;
             the screening period.The average daily alcohol consumption exceeds 2 units of alcohol&#xD;
             (1 unit = 360 mL beer Liquor or 45 mL liquor with 40% alcohol content or 150 mL grapes&#xD;
             liqueur);&#xD;
&#xD;
          8. Hypertensive patients whose blood pressure has not been satisfactorily controlled by&#xD;
             antihypertensive drugs(Sitting systolic blood pressure ≥160 mmHg during screening&#xD;
             period, and/or diastolic pressure during screening period Pressure ≥100 mmHg);&#xD;
&#xD;
          9. Sitting systolic blood pressure ≤90 mmHg during the screening period;&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding;&#xD;
&#xD;
         11. Benzodiazepines, opioids, propofol, lidoca Those who are allergic or contraindicated&#xD;
             due to their drug components;&#xD;
&#xD;
         12. Participated in other drug clinical trials as subjects in the past 3 months;&#xD;
&#xD;
         13. The investigator believes that it is not appropriate to participate in this trial;&#xD;
&#xD;
         14. A well-diagnosed heart disease (heart failure, angina pectoris, myocardial infarction,&#xD;
             heart rhythmabnormalities etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diansan Su, Dr.</last_name>
    <phone>+862168383702</phone>
    <email>diansansu@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huichen zhu, M.S.</last_name>
    <phone>+862168383702</phone>
    <email>diansansu@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai, China</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diansan Su, Dr.</last_name>
      <phone>+862168383702</phone>
      <email>diansansu@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Oriental Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai, China</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangrui D Wang, Dr.</last_name>
      <phone>13701901953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiaxing Second Hospital</name>
      <address>
        <city>Jiaxing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei zhou</last_name>
      <phone>13867300139</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingsheng zhang</last_name>
      <phone>13807915056</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>diansan su</investigator_full_name>
    <investigator_title>Vice Chair of the Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Hypoxia</keyword>
  <keyword>Efficacy and Safety</keyword>
  <keyword>Gastroscope</keyword>
  <keyword>Remimazolam</keyword>
  <keyword>Propofol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

